Analysis of Baseline Serum Lipid Profile for Predicting Clinical Outcomes of Patients with Extensive-Stage Small Cell Lung Cancer

• DOI: 10.2147/cmar.s418487
• Publication Date: 2023-07-27T03:05:14Z
• Authors: Mingshuang Wu; Yi He; Chenxi Pan
• Keywords: Baseline (sea); Lipid Profile

Serum lipids were reported to be the prognostic factors of various cancers, but their value in small cell lung cancer (SCLC) patients remains unclear. This study investigated relationship between lipid profiles and clinical outcomes extensive-stage (ES) SCLC by establishing a predictive risk classification model.We retrospectively analyzed values pretreatment serum derivatives with confirmed diagnosis ES-SCLC. Independent progression-free survival (PFS) determined univariate multivariate cox analysis. Then, nomograms established, which performance was evaluated concordance index (C-index), calibration curves, receiver operating characteristic (ROC) decision curve analyses (DCA).A total 158 included this study. Four optimal PFS-related factors, cholesterol (TC) ≥ 5.30, high-density lipoprotein (HDL-C) > 1.30, triglycerides (TG)/HDL-C 2.18, ki67 expression 70%, construct nomogram. The C-indexes training validation sets 0.758 0.792, respectively. ROC plots, DCA all suggested favorable discrimination ability. Besides, nomogram also performed better ability than expression. Nomogram-related score divided into two groups significant progression disparities.The promising based on parameters could help clinicians conveniently accurately evaluate prognosis ES-SCLC identify high-risk groups, so as formulate individualized therapeutic regimens follow-up strategies time.